TP53 and cancer: However, although modern Mdm2 antagonists have much improved activities compared to their precursors (i.e., nutlin-3), they suffer from similar weaknesses, which are limited elimination of p53wt cancer cells and the generation of p53-mutated drug resistant subpopulations.